Zacks: Brokerages Anticipate Vical Incorporated (VICL) Will Post Quarterly Sales of $180,000.00

Wall Street brokerages predict that Vical Incorporated (NASDAQ:VICL) will report $180,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Vical’s earnings, with the highest sales estimate coming in at $300,000.00 and the lowest estimate coming in at $50,000.00. Vical reported sales of $3.24 million during the same quarter last year, which indicates a negative year-over-year growth rate of 94.4%. The company is scheduled to report its next earnings results on Monday, October 22nd.

On average, analysts expect that Vical will report full-year sales of $1.75 million for the current fiscal year, with estimates ranging from $1.50 million to $2.00 million. For the next financial year, analysts expect that the company will report sales of $400,000.00. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Vical.

Vical (NASDAQ:VICL) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.05. Vical had a negative net margin of 207.71% and a negative return on equity of 33.70%. The company had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.51 million.

A number of research analysts have recently commented on VICL shares. Zacks Investment Research raised shares of Vical from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Friday, August 10th. HC Wainwright set a $4.00 price objective on shares of Vical and gave the company a “buy” rating in a research note on Wednesday, August 8th.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in shares of Vical during the 2nd quarter valued at about $205,000. Renaissance Technologies LLC grew its holdings in shares of Vical by 13.9% during the 2nd quarter. Renaissance Technologies LLC now owns 877,729 shares of the biotechnology company’s stock worth $1,009,000 after purchasing an additional 107,100 shares during the period. Finally, BlackRock Inc. grew its holdings in shares of Vical by 20.0% during the 2nd quarter. BlackRock Inc. now owns 394,320 shares of the biotechnology company’s stock worth $453,000 after purchasing an additional 65,732 shares during the period. 45.78% of the stock is owned by institutional investors.

Shares of NASDAQ VICL traded down $0.02 on Friday, reaching $1.23. 27,100 shares of the company traded hands, compared to its average volume of 173,259. Vical has a fifty-two week low of $1.02 and a fifty-two week high of $2.42. The company has a market cap of $27.27 million, a P/E ratio of -1.22 and a beta of 0.64.

Vical Company Profile

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.

Further Reading: How does inflation affect different investments?

Get a free copy of the Zacks research report on Vical (VICL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply